Banks, asset managers, payments networks, insurers, fintech, crypto-linked companies, and the capital markets around them.
The stablecoin aims to reduce fees for minting and redeeming dollars-on-chain assets and to share reserve earnings with partners, according to the Open Standard rollout.
THE APEX TIMES
THE APEX TIMES
In a note to investors, Bank of America suggested Delta Air Lines and United Airlines could be entering a favorable pricing environment, with Delta’s upcoming report seen as an early test of whether elevated fares are holding up.
THE APEX TIMES
A new market check argues Goldman Sachs’ stock has moved beyond an easy “value” bargain, pointing instead to a potential premium suggested by an intrinsic-valuation approach that contrasts expected returns with what’s already priced in.
THE APEX TIMES
In a public comment reported by financial media, Armstrong linked America’s rising debt to incentive problems in how governments set spending, and suggested that without a spending constraint and a “hard-backed” money system, reform is unlikely to stick.
THE APEX TIMES
A 24/7 Wall St. stock-prediction piece argued Coinbase shares have more upside if crypto market activity normalizes and the company’s spending reductions translate into stronger results.
THE APEX TIMES
The bank’s program is part of a growing list of large employers backing the newly launched, tax-deferred savings and investing accounts for minors.
THE APEX TIMES
A growing portion of Berkshire Hathaway’s balance sheet can generate returns without taking market risk, according to commentary on the company’s large liquidity position and how it interacts with today’s yield environment.
THE APEX TIMES
In commentary tied to JPMorgan’s risk view, the bank is warning that cybersecurity threats could prove more destabilizing than traditional credit losses, especially as artificial intelligence changes how attacks are carried out.
THE APEX TIMES
A June rating change from Morgan Stanley, cited in a roundup of Ariel Investments’ top picks, highlights Charles River Laboratories’ bets on rising biopharma demand, preclinical growth, and incremental safety-testing momentum.
